FindTrial
Sign In

Understanding the perspectives on Human Papillomavirus (HPV) in oropharyngeal cancer (OPSCC) in China: Establish a Novel Composite Risk Stratification for Surgically Resected OPSCC.

Understanding the perspectives on Human Papillomavirus (HPV) in oropharyngeal cancer (OPSCC) in China: Establish a Novel Composite Risk Stratification for Surgically Resected OPSCC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041415
Enrollment
Unknown
Registered
2020-12-25
Start date
2020-08-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OPSCC

Interventions

case series:Nil

Sponsors

Department of Oral Maxillofacial Head and Neck Oncology, the Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 100 Years

Inclusion criteria

Inclusion criteria: OPSCC whom underwent MDTmanagement in the Department of Oral Maxillofacial-Head Neck Oncology, Shanghai Ninth Peoples Hospital between January 2000 and December 2020.

Exclusion criteria

Exclusion criteria: 1. To ensure accurate information on treatment, patients with incomplete information on treatment or follow-up will be excluded. 2. To eliminate atypical treatment regimens, patients who did not undergo management will be excluded.

Design outcomes

Primary

MeasureTime frame
Related factors for HPV positive in OPSCC.;—

Secondary

MeasureTime frame
Overall survival;Disease Free Survival;Risk stratification for OPSCC;—

Countries

China

Contacts

Public ContactChenping Zhang

The Ninth People's Hospital Affiliated to Medical College of Shanghai Jiaotong University

zhang.chenping@outlook.com+86 136 0196 3645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026